Last reviewed · How we verify
Lipitor biosimilars
28 approved
0 filed
3 Phase 3
2 active patents
About Lipitor
Lipitor (atorvastatin) — originally marketed by Pfizer Inc.. Class: HMG-CoA reductase inhibitor (statin). Target: HMG-CoA reductase. Area: Metabolic. First approved 1996-12-17.
Approved biosimilars (28)
| Biosimilar | Sponsor | Phase | First approval | Country |
|---|---|---|---|---|
| Atorvastatin (generic Lipitor) | University of Pennsylvania | marketed | ||
| atorvastatin,pravastatin | Shenyang Northern Hospital | marketed | ||
| Atorvastatin, Amlodipine, Perindopril | Charles University, Czech Republic | marketed | ||
| Atorvastatin, high vs low dose | Hippocration General Hospital | marketed | ||
| Atorvastatin B | Hanmi Pharmaceutical Company Limited | marketed | ||
| Atorvastatin-pantoprazole | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | marketed | ||
| Atorvastatin and Omega-3 fatty acids | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | marketed | ||
| Atorvastatin and fenofibrate | The University of Western Australia | marketed | ||
| Atorvastatin-esomeprazole | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | marketed | ||
| Atorvastatin (Lipinon) | Seoul National University Hospital | marketed | ||
| Atorvastatin, Ezetimibe | Abant Izzet Baysal University | marketed | ||
| atorvastatin plus ezetimibe | Shanghai Jiao Tong University School of Medicine | marketed | ||
| Atorvastatin (Lipilou) | Chong Kun Dang Pharmaceutical | marketed | ||
| atorvastatin and clopidogrel | Ospedale Misericordia e Dolce | marketed | ||
| Atorvastatin (Lipitor) | University of Chicago | marketed | ||
| Atorvastatin, Probucol, Cilostazol | Otsuka Beijing Research Institute | marketed | ||
| Atorvastatin-ranitidine | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | marketed | ||
| atorvastatin 3 days | Radboud University Medical Center | marketed | ||
| Atorvastatin Calcium tablets 80mg | Sichuan Provincial People's Hospital | marketed | ||
| Atorvastatin 10mg | Copenhagen University Hospital, Hvidovre | marketed | ||
| Atorvastatin 80 mg | Organon and Co | marketed | ||
| Atorvastatin or Rosuvastatin | Wenzhou Medical University | marketed | ||
| Atorvastatin 10 mg | Organon and Co | marketed | ||
| atorvastatin 7 days | Radboud University Medical Center | marketed | ||
| Atorvastatin A | Hanmi Pharmaceutical Company Limited | marketed | ||
| Atorvastatin Calcium Tablets | NYU Langone Health | marketed | ||
| Atorvastatin-omeprazole | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | marketed | ||
| atorvastatin, aspirin, losartan, amlodipine | Russian Cardiology Research and Production Center | marketed |
Filed biosimilars under regulatory review (0)
Phase 3 biosimilars (3)
| Biosimilar | Sponsor | Phase | First approval | Country |
|---|---|---|---|---|
| Atorvastatin Calcium 20mg, QD | Kuhnil Pharmaceutical Co., Ltd. | phase 3 | ||
| Atorvastatin alone | Wenzhou Medical University | phase 3 | ||
| Atorvastatin 40mg, QD | Daewoong Pharmaceutical Co. LTD. | phase 3 |
Originator patent timeline
Active patents (2)
- —
11654106· US - —
11369567· US
Expired patents (0)
Subscribe to biosimilar updates
Every regulatory action on Lipitor or any of its biosimilars:
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing